FDA Panel Votes No on J&J RA Drug

Aug 02, 2017

Reuters

An FDA advisory panel concluded that the benefits of Johnson & Johnson's experimental rheumatoid arthritis drug, sirukumab, do not outweigh the risks.

The panel voted 12-1 against the approval of the drug, citing safety concerns.

Two days prior, a FDA report concluded that more deaths were reported in patients taking sirukumab than those taking a placebo.

Currently, there are two drugs in the same class already on the market -- Roche Holding's Actemra, and Sanofi and Regeneron Pharmaceuticals’ Kevzara.

Read the Reuters release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments